Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
- |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Inhibikase Therapeutics |
285.17 Mn |
114.80 Mn |
- |
-202.71% |
| Date | Value |
|---|
| Mar 31, 2026 |
-202.71% |
| Dec 31, 2025 |
315.57% |
| Sep 30, 2025 |
-14.31% |
| Jun 30, 2025 |
43.87% |
| Mar 31, 2025 |
82.67% |
| Dec 31, 2024 |
149.70% |
| Sep 30, 2024 |
-2.97% |
| Jun 30, 2024 |
-73.00% |
| Mar 31, 2024 |
-16.18% |
| Dec 31, 2023 |
-34.05% |
| Sep 30, 2023 |
1,056.18% |
| Jun 30, 2023 |
-626.05% |
| Mar 31, 2023 |
-747.36% |
